Home » OncoTyrol to Conduct Validation Studies on Protagen UniArray Technology

OncoTyrol to Conduct Validation Studies on Protagen UniArray Technology

Jun 10, 2009

NEW YORK (GenomeWeb News) – Protagen said today that it has formed a collaboration with OncoTyrol to conduct validation studies on the firm's UniArray technology platform.

The study aims to determine the "most robust combination of putative prostate cancer markers and optimizing the diagnostic protein biochip to proceed to clinical trials," Protagen CEO Stefan Müllner said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Scan

Spiders and Scorpions, Oh My!

The ancestors of the Arizona bark scorpion and other scorpions and spiders underwent whole-genome duplication, KJZZ reports.

Keep It Secret

A cryptographic approach could help researchers keep genomic data private while researchers analyze it, Scientific American reports.

Page Joins Chronic Disease Startup

Andy Page, the former president of 23andMe, has joined a diabetes-management startup, according to CNBC.

This Week in Cell

In Cell this week: regulatory changes in pancreatic cancer, metabolic shifts in Alzheimer's disease, and more.

What's Popular?

In Microarrays & Multiplexing

  1. Autism Appears Overrepresented in Certain Mitochondrial Haplogroups

  2. With New Instrument, Quanterix Addressing Customer Demand for Increased Flexibility, Lower Price

    Premium

Sponsorships

Privacy Policy.  Copyright © 2017 GenomeWeb LLC.  All Rights Reserved.